Citations (46)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (15)
Kyosuke Hattori, Yuji Hirano, Yasuhide Kanayama, Yosuke Hattori, Takefumi Kato, Nobunori Takahashi, Naoki Ishiguro & Toshihisa Kojima. (2021) Efficacy of add-on iguratimod in patients with rheumatoid arthritis who inadequately respond to either tocilizumab or tumor necrosis factor alpha inhibitors. Modern Rheumatology 31:1, pages 80-87.
Read now
Read now
Naoki Ishiguro, Kai Shibata, Akiko Yoshimura, Satoshi Ikeuchi & Mika Ishii. (2020) Factors influencing physician decisions to discontinue treatment after onset of liver dysfunction: Post-hoc analysis of an all-case post-marketing surveillance study of iguratimod. Modern Rheumatology 30:4, pages 633-639.
Read now
Read now
Naoki Ishiguro, Kai Shibata, Akiko Yoshimura, Satoshi Ikeuchi & Mika Ishii. (2020) Investigation of the predictors of the response to Iguratimod therapy: A post-hoc analysis of post-marketing surveillance study. Modern Rheumatology 30:4, pages 626-632.
Read now
Read now
Takahito Suto, Yukio Yonemoto, Koichi Okamura, Hideo Sakane, Kimihiko Takeuchi, Yasuyuki Tamura, Tetsuya Kaneko, Keio Ayabe & Hirotaka Chikuda. (2019) The three-year efficacy of iguratimod in clinical daily practice in patients with rheumatoid arthritis. Modern Rheumatology 29:5, pages 775-781.
Read now
Read now
Koichiro Ishikawa & Junichiro Ishikawa. (2019) Iguratimod, a synthetic disease modifying anti-rheumatic drug inhibiting the activation of NF-κB and production of RANKL: Its efficacy, radiographic changes, safety and predictors over two years’ treatment for Japanese rheumatoid arthritis patients. Modern Rheumatology 29:3, pages 418-429.
Read now
Read now
Tsuneyo Mimori, Masayoshi Harigai, Tatsuya Atsumi, Takao Fujii, Masataka Kuwana, Hiroaki Matsuno, Shigeki Momohara, Syuji Takei, Naoto Tamura, Yoshinari Takasaki, Kazuhiko Yamamoto, Satoshi Ikeuchi, Satoru Kushimoto & Takao Koike. (2019) Safety and effectiveness of iguratimod in patients with rheumatoid arthritis: Final report of a 52-week, multicenter postmarketing surveillance study. Modern Rheumatology 29:2, pages 314-323.
Read now
Read now
Hideto Kameda, Takao Fujii, Ayako Nakajima, Ryuji Koike, Akira Sagawa, Katsuaki Kanbe, Tetsuya Tomita, Masayoshi Harigai & Yasuo Suzuki. (2019) Japan College of Rheumatology guideline for the use of methotrexate in patients with rheumatoid arthritis. Modern Rheumatology 29:1, pages 31-40.
Read now
Read now
Yuki Arita, Hiroaki Taguchi, Mari Kobayashi, Toshihiro Tono, Yasuo Ohsone & Yutaka Okano. (2018) pneumonia developed in a patient with rheumatoid arthritis after 14 weeks of iguratimod add-on to treatment with methotrexate and etanercept. Modern Rheumatology 28:6, pages 1041-1043.
Read now
Read now
Ayaka Yoshikawa, Shuzo Yoshida, Yuko Kimura, Nao Tokai, Yohei Fujiki, Takuya Kotani, Yoko Matsumura, Tohru Takeuchi & Shigeki Makino. (2018) Add-on iguratimod as a therapeutic strategy to achieve remission in patients with rheumatoid arthritis inadequately responding to biological DMARDs: A retrospective study. Modern Rheumatology 28:2, pages 227-234.
Read now
Read now
Tsuneyo Mimori, Masayoshi Harigai, Tatsuya Atsumi, Takao Fujii, Masataka Kuwana, Hiroaki Matsuno, Shigeki Momohara, Syuji Takei, Naoto Tamura, Yoshinari Takasaki, Satoshi Ikeuchi, Satoru Kushimoto & Takao Koike. (2017) Safety and effectiveness of 24-week treatment with iguratimod, a new oral disease-modifying antirheumatic drug, for patients with rheumatoid arthritis: interim analysis of a post-marketing surveillance study of 2679 patients in Japan. Modern Rheumatology 27:5, pages 755-765.
Read now
Read now
Yutaka Yoshioka, Nobunori Takahashi, Atsushi Kaneko, Yuji Hirano, Yasuhide Kanayama, Hiroyasu Kanda, Hideki Takagi, Takayasu Ito, Takefumi Kato, Kiwamu Saito, Koji Funahashi, Shuji Asai, Toki Takemoto, Kenya Terabe, Nobuyuki Asai, Naoki Ishiguro & Toshihisa Kojima. (2016) Disease activity early in treatment as a predictor of future low disease activity in RA patients treated with iguratimod. Modern Rheumatology 26:2, pages 169-174.
Read now
Read now
Koichi Okamura, Yukio Yonemoto, Takahito Suto, Chisa Okura & Kenji Takagishi. (2015) Efficacy at 52 weeks of daily clinical use of iguratimod in patients with rheumatoid arthritis. Modern Rheumatology 25:4, pages 534-539.
Read now
Read now
Keiichi Tanaka, Tomonobu Yamaguchi & Masako Hara. (2015) Iguratimod for the treatment of rheumatoid arthritis in Japan. Expert Review of Clinical Immunology 11:5, pages 565-573.
Read now
Read now
Koichi Okamura, Yukio Yonemoto, Chisa Okura, Tsutomu Kobayashi & Kenji Takagishi. (2015) Efficacy of the clinical use of iguratimod therapy in patients with rheumatoid arthritis. Modern Rheumatology 25:2, pages 235-240.
Read now
Read now
Masako Hara, Naoki Ishiguro, Kou Katayama, Masakazu Kondo, Takayuki Sumida, Tsuneyo Mimori, Satoshi Soen, Kota Nagai, Tomonobu Yamaguchi & Kazuhiko Yamamoto. (2014) Safety and efficacy of combination therapy of iguratimod with methotrexate for patients with active rheumatoid arthritis with an inadequate response to methotrexate: An open-label extension of a randomized, double-blind, placebo-controlled trial. Modern Rheumatology 24:3, pages 410-418.
Read now
Read now
Articles from other publishers (31)
Jie Chen, Qincheng Che, Yuying Kou, Xing Rong, Xiaojie Zhang, Minqi Li & Qiang Shu. (2023) A novel drug combination of Tofacitinib and Iguratimod alleviates rheumatoid arthritis and secondary osteoporosis. International Immunopharmacology 124, pages 110913.
Crossref
Crossref
Yutaka Kawahito, Akio Morinobu, Yuko Kaneko, Masataka Kohno, Shintaro Hirata, Mitsumasa Kishimoto, Yohei Seto, Takahiko Sugihara, Eiichi Tanaka, Hiromu Ito, Toshihisa Kojima, Isao Matsushita, Keiichiro Nishida, Masaaki Mori, Atsuko Murashima, Hisashi Yamanaka, Takeo Nakayama, Masayo Kojima & Masayoshi Harigai. (2023) Drug treatment algorithm and recommendations from the 2020 update of the Japan College of Rheumatology clinical practice guidelines for the management of rheumatoid arthritis—secondary publication. Modern Rheumatology 33:1, pages 21-35.
Crossref
Crossref
Tianqi Zhang, Qin Shu, Huaijun Zhu, Min Wang, Na Yang, Huayong Zhang & Weihong Ge. (2023) Serum proteomics analysis of biomarkers for evaluating clinical response to MTX/IGU therapy in early rheumatoid arthritis. Molecular Immunology 153, pages 119-125.
Crossref
Crossref
Liuting Zeng, Qi He, Kailin Yang, Wensa Hao, Ganpeng Yu & Hua Chen. (2022) A Systematic Review and Meta-Analysis of 19 Randomized Controlled Trials of Iguratimod Combined With Other Therapies for Sjogren’s Syndrome. Frontiers in Immunology 13.
Crossref
Crossref
Yuji Nozaki, Motohiro Oribe, Daisuke Tomita, Tetsu Itami, Shinya Hayashi, Toshihisa Maeda, Koji Fukuda, Ryosuke Kuroda, Keiko Funahashi, Tsukasa Matsubara, Koji Kinoshita & Itaru Matsumura. (2022) Iguratimod versus salazosulfapyridine in rheumatoid arthritis patients with an inadequate response to methotrexate: Adjusted with propensity score matching. Modern Rheumatology.
Crossref
Crossref
Chao-Jun Hu, Li Zhang, Shuang Zhou, Nan Jiang, Jiu-Liang Zhao, Qian Wang, Xin-Ping Tian & Xiao-Feng Zeng. (2021) Effectiveness of iguratimod as monotherapy or combined therapy in patients with rheumatoid arthritis: a systematic review and meta-analysis of RCTs. Journal of Orthopaedic Surgery and Research 16:1.
Crossref
Crossref
Sajan Shrestha, Jing Zhao, Changqing Yang & Jinping Zhang. (2021) Iguratimod combination therapy compared with methotrexate monotherapy for the treatment of rheumatoid arthritis: a systematic review and meta-analysis. Clinical Rheumatology 40:10, pages 4007-4017.
Crossref
Crossref
Kai Shibata, Akiko Yoshimura, Satoshi Ikeuchi & Mika Ishii. (2021) Effectiveness of drug safety measures for reducing the incidence of adverse drug reactions: Post-hoc analysis of data from all-case surveillance of iguratimod using generalized estimating equations. PLOS ONE 16:7, pages e0253513.
Crossref
Crossref
L.-J. Chen, Y.-J. Zhou, Z.-H. Wen, F. Tian & J.-Y. Li. (2020) Efficacy and safety of iguratimod combined with methotrexate vs. methotrexate alone in rheumatoid arthritisWirksamkeit und Sicherheit von Iguratimod in Kombination mit Methotrexat vs. Methotrexat allein bei rheumatoider Arthritis. Zeitschrift für Rheumatologie 80:5, pages 432-446.
Crossref
Crossref
Yuji Nozaki. (2021) Iguratimod: Novel Molecular Insights and a New csDMARD for Rheumatoid Arthritis, from Japan to the World. Life 11:5, pages 457.
Crossref
Crossref
Masao Tanaka. (2021) Conflict between efficacy and economy in rheumatoid arthritis treatment: Iguratimod is found at a compromise. The Lancet Regional Health - Western Pacific 10, pages 100144.
Crossref
Crossref
Rong Mu, Chun Li, Xiaomei Li, Yao Ke, Ling Zhao, Lin Chen, Rui Wu, Zhenbiao Wu, Xiaoxia Zuo, Yanli Xie, Jinwei Chen, Wei Wei, Yi Liu, Zhijun Li, Lie Dai, Lingyun Sun, Xiangyuan Liu & Zhanguo Li. (2021) Effectiveness and safety of iguratimod treatment in patients with active rheumatoid arthritis in Chinese: A nationwide, prospective real-world study. The Lancet Regional Health - Western Pacific 10, pages 100128.
Crossref
Crossref
Wei Jiang, Lingshu Zhang, Yi Zhao, Xiong He, Chunrong Hu & Yi Liu. (2020) The efficacy and mechanism for action of iguratimod in primary Sjögren’s syndrome patients. International Ophthalmology 40:11, pages 3059-3065.
Crossref
Crossref
Asuka Inoue, Yuji Nozaki, Yasuaki Hirooka, Koji Kinoshita, Yasutaka Chiba, Masanori Funauchi & Itaru Matsumura. (2020) The Effectiveness and Retention Rate of Iguratimod in Japanese Rheumatoid Arthritis Patients with/without Methotrexate in Daily Medical Care. Life 10:11, pages 261.
Crossref
Crossref
Adam Kilian, Yu Pei Chock, Irvin J. Huang, Elizabeth R. Graef, Laura A. Upton, Aneka Khilnani, Sonia D. Silinsky Krupnikova, Ibrahim Almaghlouth, Laura C. Cappelli, Ruth Fernandez-Ruiz, Brittany A. Frankel, Jourdan Frankovich, Carly Harrison, Bharat Kumar, Kanika Monga, Jorge A. Rosario Vega, Namrata Singh, Jeffrey A. Sparks, Elaine Sullo, Kristen J. Young, Ali Duarte-Garcia, Michael Putman, Sindhu Johnson, Rebecca Grainger, Zachary S. Wallace, Jean W. Liew & Aruni Jayatilleke. (2020) Acute respiratory viral adverse events during use of antirheumatic disease therapies: A scoping review. Seminars in Arthritis and Rheumatism 50:5, pages 1191-1201.
Crossref
Crossref
Magdalena Massalska, Wlodzimierz Maslinski & Marzena Ciechomska. (2020) Small Molecule Inhibitors in the Treatment of Rheumatoid Arthritis and Beyond: Latest Updates and Potential Strategy for Fighting COVID-19. Cells 9:8, pages 1876.
Crossref
Crossref
Huihui Jiang, Hongyan Gao, Qin Wang, Miao Wang & Bin Wu. (2020) Molecular mechanisms and clinical application of Iguratimod: A review. Biomedicine & Pharmacotherapy 122, pages 109704.
Crossref
Crossref
Jie Li, Jun Bao, Jian Zeng, Aizhu Yan, Chunqiu Zhao & Qiang Shu. (2019) Iguratimod: a valuable remedy from the Asia Pacific region for ameliorating autoimmune diseases and protecting bone physiology. Bone Research 7:1.
Crossref
Crossref
Chak Sing Lau, Faith Chia, Leonila Dans, Andrew Harrison, Tsu Yi Hsieh, Rahul Jain, Seung Min Jung, Mitsumasa Kishimoto, Ashok Kumar, Khai Pang Leong, Zhanguo Li, Juan Javier Lichauco, Worawit Louthrenoo, Shue Fen Luo, Rong Mu, Peter Nash, Chin Teck Ng, Bagus Suryana, Linda Kurniaty Wijaya & Swan Sim Yeap. (2019) 2018 update of the APLAR recommendations for treatment of rheumatoid arthritis. International Journal of Rheumatic Diseases 22:3, pages 357-375.
Crossref
Crossref
Ying Xia, Shunbo Zhao, Meng Gong & Li Ding. (2018) A rapid and sensitive LC-MS/MS method for analysis of iguratimod in human plasma: Application to a pharmacokinetic study in Chinese healthy volunteers. Biomedical Chromatography 32:9, pages e4277.
Crossref
Crossref
Yoshitaka Morita. (2018) Treatment Update on Rheumatoid Arthritis関節リウマチの治療update. The Japanese Journal of Rehabilitation Medicine 55:4, pages 334-339.
Crossref
Crossref
Wenjing Xiao, Jian-Ping Guo, Chun Li, Hua Ye, Wei Wei, Yaohong Zou, Lie Dai, Zhijun Li, Miaojia Zhang, Xiangpei Li, Xiaoyan Cai, Jianhong Zhao, Youlian Wang, Yi Tao, Dongzhou Liu, Yasong Li, Min Wu, Erwei Sun, Lijun Wu, Li Luo, Rong Mu & Zhanguo Li. (2018) Genetic predictors of efficacy and toxicity of iguratimod in patients with rheumatoid arthritis. Pharmacogenomics 19:5, pages 383-392.
Crossref
Crossref
. (2018) 関節リウマチ治療におけるイグラチモドの有用性と安全性. Orthopedics & Traumatology 67:2, pages 296-299.
Crossref
Crossref
Feng Xiao, Feng Zhang, Ling-ling Zhang & Wei Wei. (2017) A randomized phase I study to evaluate the safety, tolerability, pharmacokinetics and food-effect of Iguratimod in healthy adult volunteers. European Journal of Clinical Pharmacology 74:1, pages 69-77.
Crossref
Crossref
K. Morimoto, A. Miura & Keiichi Tanaka. (2017) Anti-allodynic action of the disease-modifying anti-rheumatic drug iguratimod in a rat model of neuropathic pain. Inflammation Research 66:10, pages 855-862.
Crossref
Crossref
Z. Xia, J. Lyu, N. Hou, L. Song, X. Li & H. Liu. (2015) Iguratimod in combination with methotrexate in active rheumatoid arthritisIguratimod in Kombination mit Methotrexat bei aktiver rheumatoider Arthritis. Zeitschrift für Rheumatologie 75:8, pages 828-833.
Crossref
Crossref
Tetsuya YamamotoKyoko HasegawaMakoto OnodaKeiichi Tanaka. (2016) Pharmacokinetic and Pharmacodynamic Analyses of Drug-Drug Interactions between Iguratimod and Warfarinイグラチモドとワルファリンとの薬物相互作用に対する薬物動態学的及び薬力学的解析. YAKUGAKU ZASSHI 136:6, pages 905-911.
Crossref
Crossref
Jun Shiota, Hidetoshi Murao, Akihiko Miura, Masaaki Mikami & Keiichi Tanaka. (2016) Iguratimod, a Disease-Modifying Anti-Rheumatic Drug, Inhibits Osteoclastogenesis and Bone Resorption through Suppression of the Nuclear Factor of Activated T Cells Signaling Pathway. Open Journal of Rheumatology and Autoimmune Diseases 06:04, pages 106-119.
Crossref
Crossref
Xin-Wang Duan, Xiu-Ling Zhang, Shao-Yuan Mao, Jing-Jing Shang & Xiao-Dong Shi. (2015) Efficacy and safety evaluation of a combination of iguratimod and methotrexate therapy for active rheumatoid arthritis patients: a randomized controlled trial. Clinical Rheumatology 34:9, pages 1513-1519.
Crossref
Crossref
Satoshi Yamaori, Ken Takami, Ayaka Shiozawa, Kanako Sakuyama, Naoki Matsuzawa & Shigeru Ohmori. (2015) <i>In Vitro</i> Inhibition of CYP2C9-Mediated Warfarin 7-Hydroxylation by Iguratimod. Biological & Pharmaceutical Bulletin Biological and Pharmaceutical Bulletin 38:3, pages 441-447.
Crossref
Crossref
Keiichi Tanaka, Jun Shiota, Masaaki Mikami, Yoko Inoue, Takayuki Sumida, Isao Matsumoto & Kenzo Muramoto. (2014) The combined effects of iguratimod with anti-TNF^|^alpha; antibody on experimental arthritis models in mice. Inflammation and Regeneration 34:3, pages 157-164.
Crossref
Crossref